Declaration of Competing Interest As part of the Drug Development Department (DITEP), SC and SPV are principal investigator or sub-investigator of clinical trials from Abbvie, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, Astra Zeneca, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm S.A., Eisai, Eli Lilly, Exelixis, Forma, Gamamabs, Genentech, Inc., Glaxosmithkline, H3 Biomedicine, Inc, Hoffmann La Roche Ag, Innate Pharma, Iris Servier, Janssen Cilag, Kyowa Kirin Pharm. Dev., Inc., Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre, Roche, Sanofi Aventis, Taiho Pharma, Tesaro Inc, and Xencor. SPV has participated to advisory boards for Merck KGaA, has benefited from reimbursement for attending symposia from AstraZeneca and has received laboratory research funding from Fondation Roche France, Boehringher Ingelheim and Merck KGaA. RMC has no conflicts of interest or financial interests to disclose. SA is currently principal or subinvestigator as part of the department of medical oncology for clinical trials sponsored by Roche and BMS. SA has received during the past 5 years honoraria for advisory board and or presentations by Amgen, Roche, Astra Zeneca, Bristol Meyer Squib, MSD, Sanofi and Novartis.
PubMed
